Ahmet Demirkazik
Overview
Explore the profile of Ahmet Demirkazik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bozcuk H, Sert L, Kaplan M, Tatli A, Karaca M, Muglu H, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858018
Background: Although higher-generation TKIs are associated with improved progression-free survival in advanced NSCLC patients with EGFR mutations, the optimal selection of TKI treatment remains uncertain. To address this gap, we...
2.
Alkan A, Mizrak D, Yasar A, Karci E, Koksoy E, Urun M, et al.
J Cancer Res Ther
. 2024 Jul;
20(3):913-917.
PMID: 39023597
Introduction: Adjuvant chemoradiotherapy (CRT) is the optimal management strategy in resectable gastric cancer. There is a debate about the efficacy of more aggressive CRT plus chemotherapy regimens in adjuvant setting....
3.
Karaoglan B, Yekeduz E, Yazgan S, Mocan E, Koksoy E, Yasar H, et al.
Immunotherapy
. 2024 Jul;
16(12):821-828.
PMID: 39016058
Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear. Assessing the association of pre- and post-ICI treatment sodium levels with survival. We retrospectively analyzed patients receiving...
4.
Karadurmus N, Kaplan M, Sendur M, Urun Y, Demirci U, Karaca S, et al.
Curr Med Res Opin
. 2024 May;
40(7):1171-1178.
PMID: 38809230
Objective: To evaluate the efficacy and safety of nivolumab in the second-line (2L) or later-line (LL) treatment of patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) in real-life setting...
5.
Kahraman S, Karakaya S, Kaplan M, Sezgin Goksu S, Ozturk A, Isleyen Z, et al.
Sci Rep
. 2024 Mar;
14(1):5820.
PMID: 38461209
Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles...
6.
Mocan E, Yekeduz E, Karatas G, Yazgan S, Koksoy E, Senler F, et al.
Anticancer Drugs
. 2023 Nov;
35(2):190-194.
PMID: 38018837
Histamine and H1 receptors play a crucial role in the tumor microenvironment. Preclinical data showed that concomitant use of antihistamines and immune checkpoint inhibitors (ICIs) might increase the effect of...
7.
Karaagac M, Geredeli C, Yildirim M, Altinok T, Dede I, Inal A, et al.
J Cancer Res Ther
. 2023 Oct;
19(5):1248-1254.
PMID: 37787291
Background: Studies on single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) suggest that DNA repair capacity may have prognostic implications for disease recurrence and survival. However, there is...
8.
Guner G, Aktas B, Bugdayci Basal F, Demirkazik A, Gursoy P, Demirci U, et al.
J Cancer Res Clin Oncol
. 2023 Jul;
149(14):13271-13277.
PMID: 37480524
Purpose: Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3-5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The...
9.
Gurbuz M, Kilickap S, Bilici A, Karadurmus N, Sezer A, Sendur M, et al.
Medicine (Baltimore)
. 2022 Dec;
101(50):e32368.
PMID: 36550824
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with...
10.
Kayi Cangir A, Yumuk P, Dizbay Sak S, Akyurek S, Eralp Y, Yilmaz U, et al.
J Thorac Oncol
. 2022 Oct;
17(10):1158-1170.
PMID: 36192076
No abstract available.